deltatrials
Terminated PHASE2 INTERVENTIONAL 3-arm NCT04783389

A Study to Evaluate CBP-201, Rademikibart, in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate CBP-201 in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps

Sponsor: Connect Biopharm LLC

Conditions Chronic Rhinosinusitis With Nasal Polyps
Interventions CBP-201 Placebo
Updated 19 times since 2021 Last updated: Sep 25, 2023 Started: Jun 16, 2021 Primary completion: Apr 15, 2022 Completion: Jun 10, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Trial was discontinued in 2022 due to COVID-19 pandemic and Ukraine/Russia conflict related enrollment challenges. Discontinuation was not related to safety.

This PHASE2 trial investigates Chronic Rhinosinusitis With Nasal Polyps and is currently terminated or withdrawn. Connect Biopharm LLC leads this study, which shows 19 recorded versions since 2021 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Feb 2022 · 2 months · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~Apr 2023 · 7 months · monthly snapshot~Apr 2023 – ~Nov 2023 · 7 months · monthly snapshot~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshot~Apr 2025 – ~Sep 2025 · 5 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Apr 2025 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Sep 2024 — Apr 2025 [monthly]

    Terminated PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  5. Nov 2023 — Jul 2024 [monthly]

    Terminated PHASE2

▶ Show 14 earlier versions

  1. Apr 2023 — Nov 2023 [monthly]

    Terminated PHASE2

  2. Sep 2022 — Apr 2023 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  3. Jun 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE2

  5. Apr 2022 — May 2022 [monthly]

    Recruiting PHASE2

  6. Mar 2022 — Apr 2022 [monthly]

    Recruiting PHASE2

  7. Feb 2022 — Mar 2022 [monthly]

    Recruiting PHASE2

  8. Dec 2021 — Feb 2022 [monthly]

    Recruiting PHASE2

  9. Nov 2021 — Dec 2021 [monthly]

    Recruiting PHASE2

  10. Oct 2021 — Nov 2021 [monthly]

    Recruiting PHASE2

  11. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  12. Jun 2021 — Sep 2021 [monthly]

    Not Yet Recruiting PHASE2

  13. May 2021 — Jun 2021 [monthly]

    Not Yet Recruiting PHASE2

  14. Apr 2021 — May 2021 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Connect Biopharm LLC
Data source: Connect Biopharm LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Austin, United States , Bakersfield, United States , Barcelona, Spain , Bellingham, United States , Bengbu, China , Bialystok, Poland , Birmingham, United States , Bydgoszcz, Poland , Charleston, United States and 48 more locations